Igm Biosciences Stock Net Asset
| IGMS Stock | USD 1.31 0.04 3.15% |
Fundamental analysis of IGM Biosciences allows traders to better anticipate movements in IGM Biosciences' stock price by examining its financial health and performance throughout various phases of its business cycle.
IGM | Net Asset | Build AI portfolio with IGM Stock |
IGM Biosciences Company Net Asset Analysis
IGM Biosciences' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current IGM Biosciences Net Asset | 265.71 M |
Most of IGM Biosciences' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, IGM Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
IGM Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for IGM Biosciences is extremely important. It helps to project a fair market value of IGM Stock properly, considering its historical fundamentals such as Net Asset. Since IGM Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of IGM Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of IGM Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
IGM Total Assets
Total Assets |
|
Based on the recorded statements, IGM Biosciences has a Net Asset of 265.71 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
IGM Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses IGM Biosciences' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of IGM Biosciences could also be used in its relative valuation, which is a method of valuing IGM Biosciences by comparing valuation metrics of similar companies.IGM Biosciences is currently under evaluation in net asset category among its peers.
IGM Biosciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of IGM Biosciences from analyzing IGM Biosciences' financial statements. These drivers represent accounts that assess IGM Biosciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of IGM Biosciences' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 2.7B | 982.0M | 706.7M | 434.7M | 369.7M | 557.2M | |
| Enterprise Value | 2.5B | 877.4M | 626.6M | 362.7M | 388.4M | 508.7M |
IGM Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in IGM Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of IGM Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing IGM Biosciences' value.| Shares | Northern Trust Corp | 2025-03-31 | 187 K | Two Sigma Investments Llc | 2025-03-31 | 139.8 K | Charles Schwab Investment Management Inc | 2025-03-31 | 125.6 K | Verition Fund Managegment, Llc | 2025-03-31 | 119.1 K | Bruce & Co Inc | 2025-03-31 | 100 K | Eagle Bay Advisors Llc | 2025-06-30 | 99.6 K | Two Sigma Advisers, Llc | 2025-03-31 | 90.5 K | Acadian Asset Management Llc | 2025-03-31 | 85.8 K | Woodline Partners Lp | 2025-03-31 | 69.6 K | Baker Bros Advisors Lp | 2025-03-31 | 4.1 M | Siren, L.l.c. | 2025-03-31 | 3.3 M |
IGM Fundamentals
| Return On Equity | -2.46 | ||||
| Return On Asset | -0.37 | ||||
| Operating Margin | (62.17) % | ||||
| Current Valuation | (31.71 M) | ||||
| Shares Outstanding | 34.8 M | ||||
| Shares Owned By Insiders | 37.21 % | ||||
| Shares Owned By Institutions | 53.41 % | ||||
| Number Of Shares Shorted | 404.56 K | ||||
| Price To Earning | (7.72) X | ||||
| Price To Book | 109.51 X | ||||
| Price To Sales | 28.51 X | ||||
| Revenue | 2.68 M | ||||
| Gross Profit | (129.42 M) | ||||
| EBITDA | (199.47 M) | ||||
| Net Income | (195.79 M) | ||||
| Cash And Equivalents | 469.14 M | ||||
| Cash Per Share | 10.95 X | ||||
| Total Debt | 45.19 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 10.79 X | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (153 M) | ||||
| Short Ratio | 0.34 X | ||||
| Earnings Per Share | (3.27) X | ||||
| Target Price | 1.12 | ||||
| Number Of Employees | 54 | ||||
| Beta | 0.48 | ||||
| Market Capitalization | 76.44 M | ||||
| Total Asset | 265.71 M | ||||
| Retained Earnings | (1.02 B) | ||||
| Working Capital | 155.98 M | ||||
| Current Asset | 1.23 M | ||||
| Current Liabilities | 3.37 M | ||||
| Net Asset | 265.71 M |
About IGM Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze IGM Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of IGM Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of IGM Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for IGM Stock Analysis
When running IGM Biosciences' price analysis, check to measure IGM Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IGM Biosciences is operating at the current time. Most of IGM Biosciences' value examination focuses on studying past and present price action to predict the probability of IGM Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IGM Biosciences' price. Additionally, you may evaluate how the addition of IGM Biosciences to your portfolios can decrease your overall portfolio volatility.